Funding Success: SonoVascular Advances with Series A Close
SonoVascular, Inc., an innovative clinical-stage medical device firm, has taken a significant step forward by securing its first close of a $6 million Series A preferred stock financing. With Harbright Ventures leading the investment, the company aims to enhance its groundbreaking SonoThrombectomy™ System, designed for the treatment of venous thromboembolism (VTE).
SonoVascular's Revolutionary Technology
The SonoThrombectomy System employs ultrasound technology and thrombolytics to treat blood clots more effectively than current methods. By incorporating microbubble-mediated cavitation, this system allows for maximal clot reduction without causing blood loss or vascular trauma, making it a standout option for treating deep vein thrombosis (DVT).
Transforming DVT Treatment
Recently, the SonoThrombectomy System exhibited remarkable success in a First-In-Human (FIH) study conducted in South America, effectively treating ten patients with DVT. According to independent evaluations, the system achieved a complete 100% reduction in clot burden, all without adverse events related to the device. After 30 days and six months, follow-up studies revealed sustained improvements in patients' conditions.
Expert Insights on the SonoThrombectomy System
Dr. Lisandro Carnero-Vidal, a leading vascular surgeon involved in the study, highlighted the potential of the SonoThrombectomy System. He noted, "Current treatments present significant risks including blood loss and endothelial damage. Our initial findings from the feasibility study suggest that this technology may change the approach to DVT management, reinforcing safety and efficacy." His enthusiasm reflects the transformative possibilities the SonoThrombectomy offers for patients.
Supporting Better Patient Outcomes
Robert Ross from Harbright Ventures expressed confidence in SonoVascular's approach to solving longstanding problems associated with DVT treatments. He stated, "With strong FIH results, SonoVascular is poised to become the new standard of care, enabling healthcare facilities to optimize their resource use and ultimately providing better care for patients. This also has the potential to alleviate pressure on intensive care units and the wider healthcare system."
Future Plans and Milestones
The financing from the Series A round will be pivotal for achieving key objectives throughout the coming year. The company aims to secure FDA approval for an American pivotal study focused on peripheral venous applications, alongside conducting a FIH study targeting pulmonary embolism (PE) treatments.
About Venous Thromboembolism
Venous thromboembolism presents a serious threat, with up to 900,000 events occurring annually in the United States alone. A significant proportion of individuals suffering from DVT experience long-term complications, a condition known as post-thrombotic syndrome (PTS). This syndrome can worsen to a point where it severely affects a person’s quality of life. Additionally, if a clot dislodges, it may travel to the lungs, leading to a potentially fatal pulmonary embolism (PE).
Understanding SonoVascular, Inc.
SonoVascular's SonoThrombectomy System represents a noteworthy advancement in combating VTE, employing ultrasound technology to enhance thrombolytic therapy. This innovative solution aims to optimize treatment outcomes by prioritizing patient safety while minimizing harmful side effects. Based in Chapel Hill, NC, SonoVascular is focused on redefining thrombosis care, ensuring the best possible results for patients.
About Harbright Ventures
Harbright Ventures specializes in early-stage investment, concentrating on supporting innovative companies that can disrupt existing market norms. Their dedication to groundbreaking developments across various sectors reflects their commitment to improving not just the lives of individuals directly involved in the treatments, but also broader societal health outcomes.
Frequently Asked Questions
What is SonoVascular's main product?
The main product of SonoVascular is the SonoThrombectomy System, designed to treat venous thromboembolism using advanced ultrasound technology.
What are the benefits of the SonoThrombectomy System?
This system enhances safety during thrombectomy procedures, reduces clot burden, and prevents blood loss, improving overall patient outcomes.
Who led the Series A funding for SonoVascular?
Harbright Ventures led the Series A funding round aimed at advancing the SonoThrombectomy System.
What will the funding be used for?
The funding will facilitate securing FDA approval for a pivotal study in peripheral venous applications and initiating a FIH study for pulmonary embolism.
Where is SonoVascular located?
SonoVascular is headquartered in Chapel Hill, North Carolina, overseeing the development and advancements of its innovative medical technologies.
